Safety and Dose Finding Study of Oral MP470, a Multi-targeted Tyrosine Kinase Inhibitor, in Combination With Standard-of-Care Chemotherapy Regimens

Inclusion Criteria:

1. Malignant disease appropriate for initiating treatment with
carboplatin/paclitaxel, carboplatin/etoposide, topotecan, docetaxel, or erlotinib.

2. Must be able to read, understand, and sign the IRB approved Informed Consent Form.

3. At least 18 years old.

4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

5. Adequate bone marrow function; normal renal and hepatic function, normal cardiac
function.

Exclusion Criteria:

1. Any other active invasive malignancy except non-melanoma skin cancers or cervical
carcinoma in situ.

2. History of significant cardiovascular disease such as uncontrolled or symptomatic
arrhythmias, congestive heart failure and/or myocardial infarction.

3. Received any anticancer agent(s) within the past 3 weeks, including investigational
agents, chemotherapy (6 weeks for nitrosoureas or mitomycin), immunotherapy, biologic
or hormonal therapy other than LHRH agonists.

4. Received prior radiation therapy within the past 4 weeks.

5. Any serious, uncontrolled active infection that requires systemic treatment or known
infection with HIV, HCV or HBV.

6. Patient requires treatment with immunosuppressive agents other than corticosteroids
appropriate for the SOC chemotherapy regimen or those at stable doses for at least 2
weeks.